Promising Three-Drug cocktail targets Hard-to-Treat leukemia
NCT ID NCT07486726
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a combination of three drugs—aclarubicin, azacitidine, and venetoclax—in people with acute myeloid leukemia (AML) who are either newly diagnosed and unable to tolerate standard chemotherapy, or whose cancer has returned or not responded to treatment. The trial has two phases: first, to find the safest dose of aclarubicin, and second, to see how well the combo works at achieving remission. Up to 112 adults will take part across multiple centers.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- aclarubicin (a chemotherapy drug) combined with azacitidine and venetoclax
- What this could lead to
- If successful, this could offer a new treatment option for AML patients who cannot tolerate standard intensive chemotherapy, potentially improving remission rates.
- What could go wrong
- This is an early phase 1/2 trial with only 112 participants, so results are preliminary. The combination may cause side effects or fail to work better than existing treatments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA (AML) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai
Shanghai, China
-
Shanghai Jing'an District Beizhan Hospital
Shanghai, China
-
Shanghai Traditional Chinese Medicine Hospital
Shanghai, China
-
Tongren Hospital, Shanghai Jiao Tong University School of Medicine
Shanghai, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new pill boost the power of an existing leukemia treatment?
- Can a new drug combo outperform standard care for a tough blood cancer?
- Can donor immune cells fight leukemia relapse after transplant?
- Can a liposomal chemo combo outsmart tough leukemias?
- Massive AML trial aims to find best chemo and transplant protection for younger patients
- New drug cocktail aims to stop leukemia return after transplant